What'S The Difference Between Mounjaro And Zepbound? - Guide | Cured Pharmacy

What'S The Difference Between Mounjaro And Zepbound?

WEIGHT LOSS · 20 MIN READ
Written by Cured Pharmacy
Published on 14 August 2026
★★★★★ Judge.me Reviews
Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From£145.00£124.99 UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment → ✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 15 August 2026

If you have been scrolling through weight loss forums, chatting to your GP, or just trying to make sense of the headlines, you have almost certainly stumbled across two names that sound suspiciously similar: Mounjaro and Zepbound. Both contain the same active ingredient. Both come from the same pharmaceutical company. And both are generating an extraordinary amount of conversation in the weight management space right now. Yet somehow, they are not quite the same thing, and the distinction genuinely matters when you are trying to decide what is right for your health. Understanding what's the difference between Mounjaro and Zepbound is not just academic curiosity — it has real, practical implications for how you access treatment, what you pay, and what your prescription actually covers.

Summary

Mounjaro and Zepbound are both tirzepatide-based injectable medications developed by Eli Lilly. While they share identical active ingredients and mechanisms, they are approved for different clinical indications, carry different brand identities, and have distinct regulatory histories across different countries.

Here is a quick snapshot of what this article covers:

  • Both Mounjaro and Zepbound contain tirzepatide, a dual GIP and GLP-1 receptor agonist
  • Mounjaro is licensed in the UK for type 2 diabetes management; Zepbound is the US-branded weight loss version
  • In the UK in 2026, Mounjaro is the brand name used for both diabetes and weight loss under separate approvals
  • Zepbound is not currently available as a distinct product in the UK market
  • Patients in the UK accessing tirzepatide for weight loss do so via Mounjaro, typically through private prescription services

What Is Tirzepatide and How Does It Work?

Tirzepatide Weight Loss Timeline Estimator

Enter your details below to get a personalised estimated weight loss timeline based on clinical trial data for tirzepatide.

To truly understand the distinction between these two products, you first need to understand tirzepatide itself. Tirzepatide is a synthetic peptide that mimics the action of two naturally occurring gut hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Most weight loss injections people have heard about, including Wegovy (semaglutide), target only the GLP-1 pathway. Tirzepatide targets both simultaneously, which is part of what makes it so clinically remarkable.

When you inject tirzepatide once a week, it essentially sends two hormonal signals at the same time. The GLP-1 component slows gastric emptying, reduces appetite, increases insulin secretion when blood glucose is elevated, and suppresses glucagon. The GIP component adds an additional layer of metabolic signalling that appears to amplify fat burning and improve insulin sensitivity beyond what GLP-1 alone achieves. The result, as demonstrated repeatedly in the SURMOUNT trial series, is some of the most impressive weight loss figures ever recorded in a pharmacological intervention. Understanding what's the difference between Mounjaro and Zepbound starts here, because both are simply this same molecule rebranded for different markets and different purposes.

  • Tirzepatide is a dual GIP/GLP-1 receptor agonist administered once weekly via subcutaneous injection
  • It works on appetite regulation, gastric emptying speed, blood sugar control and fat metabolism
  • It outperforms single GLP-1 agonists like semaglutide in head-to-head weight loss comparisons
  • It is manufactured by Eli Lilly under different brand names depending on market and indication

What's the Difference Between Mounjaro and Zepbound in Clinical Terms?

Here is where the answer gets genuinely interesting. From a pharmacological standpoint, Mounjaro and Zepbound are the same drug. Same molecule, same mechanism, same formulations. But the regulatory and commercial distinction between them is significant. Mounjaro was the original brand name Eli Lilly used when tirzepatide was first approved by the US Food and Drug Administration (FDA) in May 2022, specifically for the treatment of type 2 diabetes in adults. When it later sought approval for chronic weight management as a standalone indication, the company made a strategic decision to launch it under a separate brand name: Zepbound, which received FDA approval in November 2023.

This is not unusual in pharmaceutical history. Separate brand names for the same molecule across different indications help companies manage prescribing pathways, insurance reimbursement categories, and patient populations. It also allows distinct marketing campaigns targeted at different audiences: endocrinologists managing diabetes on one hand, and obesity medicine specialists on the other. What's the difference between Mounjaro and Zepbound in practice then? In the United States, the split matters for insurance coverage, prior authorisation requirements, and how a prescription is written. In the UK, the picture looks quite different.

  • Mounjaro: Eli Lilly's original tirzepatide brand, first approved for type 2 diabetes
  • Zepbound: US brand name for tirzepatide approved specifically for chronic weight management
  • Both contain identical active ingredients at identical dose strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg)
  • The split is a commercial and regulatory decision, not a pharmacological one
  • Zepbound is not available as a separate product in the UK as of 2026

UK Availability and Regulatory Status in 2026

If you are based in the UK and you have searched for Zepbound, you may have found American articles or forum posts referencing it. This can create real confusion, particularly when you are trying to make a clinical decision about your own health. The reality in 2026 is straightforward: Zepbound does not exist as a separately licensed product in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Mounjaro as the single tirzepatide brand across both its indications here.

Mounjaro received UK approval for type 2 diabetes management in November 2022, following its European Medicines Agency (EMA) authorisation. The weight management indication followed, with NICE publishing guidance in 2023 and 2024 to support its use in adults with obesity, subject to defined BMI and comorbidity criteria. In England, NHS access via specialist services has been phased in gradually. However, the vast majority of people in the UK who are currently using Mounjaro for weight loss are doing so through private prescription services. This is where platforms like Cured Pharmacy's weight loss service become genuinely valuable, connecting patients with UK-registered prescribers who can assess suitability and issue a legal private prescription quickly and discreetly.

  • Zepbound is not licensed or available in the UK as a distinct product in 2026
  • Mounjaro is the UK's sole tirzepatide brand, approved for both diabetes and weight loss
  • NICE guidance supports Mounjaro for weight management under specific clinical criteria
  • NHS access remains limited; most UK patients access it via private prescription
  • UK prescribing uses the same pen device and dose titration schedule as US Zepbound

Dosing, Administration and Side Effect Profiles

Because Mounjaro and Zepbound are the same molecule, their dosing schedules are identical. Treatment always begins at 2.5mg once weekly for the first four weeks. This is a titration dose designed to allow the body to adjust gradually and minimise gastrointestinal side effects. After four weeks, the dose increases to 5mg weekly. Subsequent increases of 2.5mg every four weeks are then possible, based on tolerability and clinical response, up to a maximum maintenance dose of 15mg weekly. This gentle escalation approach is one reason why most patients tolerate tirzepatide reasonably well, even though nausea and digestive discomfort are common in the early weeks.

The side effect profile for Mounjaro and Zepbound is identical because, again, they are the same drug. The most frequently reported effects include nausea, vomiting, diarrhoea, constipation, reduced appetite, and injection site reactions. These tend to be most pronounced after dose increases and generally settle within a few weeks as the body acclimatises. Serious but rare side effects include pancreatitis, gallbladder problems, and a theoretical risk of thyroid C-cell tumours based on rodent studies, though this has not been confirmed in human clinical trials. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide. Understanding what's the difference between Mounjaro and Zepbound in terms of safety is therefore simple: there is none. The risk profile is shared.

  • Starting dose is 2.5mg once weekly, escalating every four weeks to a maximum of 15mg
  • Common side effects: nausea, diarrhoea, constipation, vomiting, fatigue
  • Side effects are most prominent after dose increases and typically self-resolve
  • Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2
  • Injection is subcutaneous, typically in abdomen, thigh, or upper arm

Cost, Access and Private Prescription Options

Cost is where the conversation around what's the difference between Mounjaro and Zepbound becomes most practically relevant for UK patients. In the United States, Zepbound was initially priced at around $1,059 per month at launch, though Eli Lilly later introduced a self-pay programme at significantly reduced rates. Mounjaro for diabetes carried a similar list price. This cost asymmetry matters in the US because insurance coverage differs between the two brands. In the UK, this simply does not apply in the same way because both indications are covered by the single Mounjaro brand.

On the NHS, Mounjaro for weight management remains accessible mainly through tier 3 specialist weight management services for now, with broader rollout planned. Privately, costs vary considerably between providers. At Cured Pharmacy, patients benefit from transparent pricing, a free private prescription included with their order, and the reassurance of UK-based prescribers carrying out a full online medical consultation before any medication is dispensed. The service is discreet, fast, and genuinely patient-centred in a way that larger, more impersonal platforms can struggle to replicate. If you are a new patient, you can use the discount code FIRST20 to save £20 on your first order, which makes starting your treatment that much more accessible.

One specific advantage Cured Pharmacy offers is that clinicians assess each patient individually, reviewing full medical history, current medications, BMI, and relevant comorbidities before prescribing. There is no one-size-fits-all approach. Prescriptions are issued by regulated professionals, and medications are dispensed from a GPhC-registered pharmacy. This level of governance is not universal across private weight loss providers, so it is worth choosing carefully.

  • NHS access to Mounjaro for weight loss remains limited to specialist services in 2026
  • Private prescriptions are the most accessible route for most UK patients currently
  • Cured Pharmacy includes a free private prescription and offers discreet delivery
  • Use code FIRST20 to save £20 on your first Mounjaro order at Cured Pharmacy
  • Always ensure your provider uses UK-registered prescribers and a GPhC-registered dispensing pharmacy

Who Should Choose Mounjaro and How to Get Started

Now that we have established what's the difference between Mounjaro and Zepbound, the more useful clinical question becomes: who is Mounjaro actually suitable for? NICE guidance recommends tirzepatide for adults with a BMI of 35 kg/m² or above, alongside at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease. Adults with a BMI of 30 to 34.9 kg/m² may also be considered under certain circumstances. The medication is intended for use alongside a reduced calorie diet and increased physical activity, not as a standalone solution.

It is worth noting that Mounjaro is not appropriate for everyone. People with type 1 diabetes, severe gastrointestinal disease, pregnancy, or certain endocrine disorders should not use it. People taking insulin or other diabetes medications should be closely monitored to avoid hypoglycaemia. If you are unsure whether you qualify, the best first step is a thorough online consultation with a qualified prescriber. At Cured Pharmacy, this process is handled entirely online, meaning you can begin your assessment from home and receive your medication delivered discreetly to your door, without needing to visit a clinic. For those who have been struggling with weight for years and have found other approaches ineffective, tirzepatide can represent a genuine turning point. Many patients describe the appetite suppression as unlike anything they have experienced before; a quiet in the background noise of food preoccupation that many people with obesity live with daily.

Supporting your weight loss journey with broader lifestyle measures is important too. Ensuring adequate micronutrient intake, particularly if you are eating significantly less, is something many patients overlook. Vitamins and supplements may be worth discussing with your prescriber as part of your overall care plan. If you experience any digestive side effects during titration, staying hydrated and eating smaller, slower meals tends to help considerably.

  • NICE recommends Mounjaro for BMI 35+ with at least one weight-related comorbidity
  • BMI 30 to 34.9 may qualify depending on individual clinical circumstances
  • Not suitable for type 1 diabetes, pregnancy, MEN2, or severe GI disease
  • An online consultation with a UK-registered prescriber is the correct starting point
  • Cured Pharmacy provides a fully guided, regulated private prescription pathway

Mounjaro vs Zepbound: Full Comparison Table

Feature Mounjaro (UK) Zepbound (US)
Active ingredient Tirzepatide Tirzepatide
Manufacturer Eli Lilly Eli Lilly
Primary approval Type 2 diabetes (UK, Nov 2022) Chronic weight management (FDA, Nov 2023)
Weight loss approved? Yes, via MHRA/NICE guidance Yes (primary US indication)
Available in UK? Yes No (not a UK licensed product)
Dose range 2.5mg to 15mg weekly 2.5mg to 15mg weekly
Injection device KwikPen (autoinjector) Autoinjector pen
Pharmacology Dual GIP/GLP-1 receptor agonist Dual GIP/GLP-1 receptor agonist
Side effects Nausea, diarrhoea, constipation, vomiting Nausea, diarrhoea, constipation, vomiting
NHS availability Limited; specialist services only N/A (US market)
Private prescription Yes, via services like Cured Pharmacy N/A in UK
Cost (private, UK) From £124.99 at Cured Pharmacy Not applicable in UK
Key clinical trial SURMOUNT-1, SURPASS programme SURMOUNT-1, SURMOUNT-2

Key Takeaways

  • Mounjaro and Zepbound are the same tirzepatide molecule, simply marketed under different brand names for different markets and clinical indications
  • In the UK, Mounjaro is the only available tirzepatide product and covers both diabetes and weight management; Zepbound does not exist here as a separate product
  • Both follow identical dosing schedules starting at 2.5mg weekly and both carry identical side effect profiles because the pharmacology is identical
  • UK patients seeking tirzepatide for weight loss should access it through a properly regulated private prescription service such as Cured Pharmacy, which offers UK-based prescribers and discreet delivery from a GPhC-registered pharmacy
  • Use the discount code FIRST20 to save £20 on your first Mounjaro order through Cured Pharmacy and begin your treatment with confidence under full clinical oversight

When to Seek Professional Advice

Weight loss medications are not over-the-counter purchases, and tirzepatide is certainly not a product you should attempt to obtain without proper medical oversight. You should seek advice from a qualified healthcare professional before starting Mounjaro if you have any history of pancreatitis, gallbladder disease, diabetic retinopathy, kidney impairment, or are taking insulin or sulphonylureas. If you develop severe abdominal pain, persistent vomiting, signs of a hypoglycaemic episode, or notice any unusual lump in your neck during treatment, contact your prescriber or GP immediately. Pregnant women, those breastfeeding, or those planning pregnancy should not use tirzepatide.

If you have been reading about weight loss injections and are unsure whether Mounjaro is right for you, the most important thing you can do is start with a proper consultation rather than relying solely on internet research. A qualified prescriber can assess your full medical history, review your current medications for interactions, and give you an honest clinical opinion about whether tirzepatide is appropriate for your situation. Services like Cured Pharmacy make this process genuinely accessible, removing the need to travel or wait weeks for an appointment. You can also explore all available weight loss treatments to compare your options before committing to a specific medication.

Scientific References

  1. NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity in adults, NICE, 2024 [Accessed 15 August 2026]
  2. European Medicines Agency: Mounjaro EPAR summary, EMA, 2022 [Accessed 15 August 2026]
  3. MHRA: Regulatory approval of Mounjaro (tirzepatide), MHRA, 2022 [Accessed 15 August 2026]
  4. Electronic Medicines Compendium: Mounjaro SmPC, EMC, 2023 [Accessed 15 August 2026]
  5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity, New England Journal of Medicine, 2022 [Accessed 15 August 2026]
  6. Ludvik B et al. Tirzepatide versus insulin degludec in patients with type 2 diabetes, The Lancet, 2021 [Accessed 15 August 2026]
  7. Nauck MA and D'Alessio DA. Tirzepatide: a new approach in the treatment of type 2 diabetes, BMJ, 2023 [Accessed 15 August 2026]
  8. Diabetes UK: Management of type 2 diabetes in adults, Diabetes UK, 2023 [Accessed 15 August 2026]
  9. British National Formulary: Tirzepatide monograph, BNF, 2024 [Accessed 15 August 2026]
  10. NHS: Tirzepatide – uses, dose, side effects and warnings, NHS, 2024 [Accessed 15 August 2026]
  11. NICE Guideline NG28: Obesity in adults: identification, assessment and management, NICE, 2023 update [Accessed 15 August 2026]
  12. Del Prato S et al. Tirzepatide for type 2 diabetes: SURPASS programme outcomes, Lancet Diabetes and Endocrinology, 2023 [Accessed 15 August 2026]
  13. Frías JP et al. Tirzepatide versus semaglutide in type 2 diabetes, Diabetes, Obesity and Metabolism, 2022 [Accessed 15 August 2026]
  14. MHRA: Guidance on using GLP-1 receptor agonists and tirzepatide, MHRA, 2024 [Accessed 15 August 2026]
  15. NICE Technology Appraisal TA924: Semaglutide for managing overweight and obesity, NICE, 2023 [Accessed 15 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

Is Zepbound available to buy in the UK?

Zepbound is not available as a separately licensed product in the UK. In the UK, tirzepatide is only available under the brand name Mounjaro, which covers both type 2 diabetes and weight management indications. UK patients looking for tirzepatide-based treatment should look specifically for Mounjaro through a regulated private prescription service or NHS pathway.

Can you take Mounjaro if you do not have diabetes?

Mounjaro can be prescribed for weight management in adults without diabetes, provided you meet the eligibility criteria set by NICE, typically a BMI of 35 kg/m² or above alongside at least one weight-related health condition. A UK-registered prescriber can assess your individual suitability during an online consultation before issuing a private prescription.

How long does it take to see results with Mounjaro?

Mounjaro results typically begin to show within the first four to twelve weeks of treatment, with appetite suppression often noticed quite quickly after starting. Clinically significant weight loss of ten percent or more body weight is generally seen over 24 to 52 weeks in those who tolerate the full titration schedule, according to SURMOUNT trial data.

What is the dose of Mounjaro for weight loss?

The starting dose of Mounjaro for weight loss is 2.5mg once weekly for four weeks, then increasing to 5mg weekly. The dose is then escalated by 2.5mg every four weeks based on tolerability, up to a maximum maintenance dose of 15mg once weekly. Your prescriber will guide your titration schedule based on your individual response and side effects.

Back to blog